Next Up

Biologics 2024

13 - 15 March 2024 |

London, UK

13 - 15 March 2024

London, UK

Europe’s Premier Meeting for Biologics R&D

Sep 2024
September 2024

mRNA Vaccines & Oligonucleotide Therapies 2024  

Sep 2024
September 2024

Biologics US 2024

Highlights

The Current Landscape of ADC Approvals and Market Trends
Industry Spotlight
While a recent spike in ADC approvals may not last forever, Antikor Biopharma’s Mahendra Deonarain asserts that antibody-drug conjugates are here to stay.
Edited by Ben Norris |
05 December 2023
Proteins & Antibodies
Industry Spotlight
Edited by Tom Cohen |
16 Nov 2023
Proteins & Antibodies
Industry Spotlight
Edited by Ben Norris |
13 Nov 2023
Proteins & Antibodies

In-Depth

Insight Article
How are oligo therapeutics revolutionising genetic disease treatments through precise targeting and transformative therapies? In this article, we explore how they provide precise gene expression interference for untreatable conditions by directly targeting disease-associated proteins and genetic mutations.
01 August 2023
Insight Article
As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape.
10 July 2023

Industry Spotlight

Industry Spotlight
While a recent spike in ADC approvals may not last forever, Antikor Biopharma’s Mahendra Deonarain asserts that antibody-drug conjugates are here to stay.
05 December 2023
Industry Spotlight
While bispecific antibodies target two specific entities, multispecific antibodies can target more than two. The use of these engineered antibodies offers the potential for enhanced therapeutic strategies by simultaneously addressing multiple aspects of a disease.
16 November 2023
Industry Spotlight
Advancements in cytokine understanding and synthetic immunology enable precise immune modulation, particularly in cancer treatment. However, challenges like short half-lives and side effects impact their wider clinical application.
13 November 2023
Industry Spotlight
Discussing using a computational drug discovery platform for the development of multispecific antibody therapeutics.
27 October 2023